Baxdrostat

A medication used in the treatment of hypertension

Baxdrostat
File:Baxdrostat.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Baxdrostat is a medication that acts as an inhibitor of the enzyme aldosterone synthase, which is involved in the production of the hormone aldosterone. It is primarily used in the treatment of hypertension, particularly in cases where patients have resistant hypertension that does not respond adequately to standard treatments.

Mechanism of Action

Baxdrostat works by selectively inhibiting the enzyme aldosterone synthase, also known as CYP11B2. This enzyme is responsible for the final step in the biosynthesis of aldosterone, a hormone that plays a crucial role in regulating blood pressure by controlling the balance of sodium and potassium in the body. By inhibiting aldosterone production, baxdrostat helps to lower blood pressure in patients with hypertension.

Clinical Use

Baxdrostat is indicated for use in patients with hypertension, particularly those with resistant forms of the condition. Resistant hypertension is defined as blood pressure that remains above target levels despite the use of three or more antihypertensive medications, including a diuretic.

Pharmacokinetics

The pharmacokinetic profile of baxdrostat includes its absorption, distribution, metabolism, and excretion. After oral administration, baxdrostat is absorbed into the bloodstream and distributed throughout the body. It is metabolized primarily in the liver and excreted via the kidneys.

Side Effects

Common side effects of baxdrostat may include dizziness, fatigue, and hyperkalemia, which is an elevated level of potassium in the blood. Patients taking baxdrostat should be monitored for changes in electrolyte levels, particularly potassium.

Development and Approval

Baxdrostat was developed as part of ongoing efforts to find effective treatments for hypertension, especially in patients who do not respond to conventional therapies. It represents a novel approach by targeting the hormonal regulation of blood pressure.

Related pages

• Hypertension
• Aldosterone
• CYP11B2
• Resistant hypertension